الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 120 |  |  |
| | | from | 120 | | |
Abstract
As the COVID-19 pandemic persists, an increasing number of patients
are suffering from loss of smell, which is now a well-known symptom of the
disease.
Loss of smell significantly impacts the quality of life of COVID-19
patients; therefore, its diagnosis and treatment should be prioritized. Unfortunately,
the lack of a clear understanding of the molecular mechanisms of olfactory
dysfunction has resulted in limited treatment options.
The olfactory system exhibits unique neural plasticity that is not found in
other parts of the central nervous system, with neurogenesis in the neuroepithelium
and parts of the olfactory tract continuing throughout a person’s life. This suggests
that certain interventions could help restore the sense of smell by awakening
olfactory neurons or modulating neural function.
OT is an intervention that improves olfactory function through frequent
sniffing and/or exposure to strong odors. However, the gold standard for treating
loss of smell remains unknown.
Oral corticosteroids can often improve olfactory function;however, their
effect is often short-lived and disappears with the discontinuation of treatment.
Therefore, the use of oral corticosteroids is strongly contraindicated by the World
Health Organization. However, long-term improvement has been reported with the
use of intranasal steroids.
So, this is randomized clinical trial was carried out in Suez Canal
University Hospital at ENT department from February 2022 to July2022 to
evaluate the efficacy of Fluticasone nasal spray and smell retraining therapy on
post COVID-19 anosmia.